HomeCompareNSTKF vs JNJ

NSTKF vs JNJ: Dividend Comparison 2026

NSTKF yields 6.73% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NSTKF wins by $931.00 in total portfolio value
10 years
NSTKF
NSTKF
● Live price
6.73%
Share price
$22.29
Annual div
$1.50
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,032.15
Full NSTKF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NSTKF vs JNJ

📍 NSTKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNSTKFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NSTKF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NSTKF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NSTKF
Annual income on $10K today (after 15% tax)
$571.98/yr
After 10yr DRIP, annual income (after tax)
$877.33/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,108.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NSTKF + JNJ for your $10,000?

NSTKF: 50%JNJ: 50%
100% JNJ50/50100% NSTKF
Portfolio after 10yr
$30.7K
Annual income
$2,860.78/yr
Blended yield
9.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NSTKF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NSTKF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNSTKFJNJ
Forward yield6.73%2.13%
Annual dividend / share$1.50$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$31.2K$30.3K
Annual income after 10y$1,032.15$4,689.40
Total dividends collected$8.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NSTKF vs JNJ ($10,000, DRIP)

YearNSTKF PortfolioNSTKF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,373$672.91$10,592$272.30+$781.00NSTKF
2$12,884$715.23$11,289$357.73+$1.6KNSTKF
3$14,543$757.27$12,123$472.89+$2.4KNSTKF
4$16,360$798.87$13,141$629.86+$3.2KNSTKF
5$18,345$839.88$14,408$846.81+$3.9KNSTKF
6$20,510$880.17$16,021$1,151.60+$4.5KNSTKF
7$22,865$919.64$18,122$1,588.22+$4.7KNSTKF
8$25,424$958.18$20,930$2,228.20+$4.5KNSTKF
9$28,199$995.71$24,792$3,191.91+$3.4KNSTKF
10$31,205$1,032.15$30,274$4,689.40+$931.00NSTKF

NSTKF vs JNJ: Complete Analysis 2026

NSTKFStock

PAO NOVATEK, an independent oil and gas company, engages in the acquisition, exploration, development, production, processing, marketing, and export of natural gas and liquid hydrocarbons. The company principally holds interests in reserves located in the Yamal-Nenets Autonomous Region, Western Siberia. It sells natural gas, stable gas condensate, gas condensate refined products, liquefied petroleum gas, crude oil, naphtha, diesel fuel, jet fuel, methanol, and petrol. The company also provides transportation, geological and geophysical research, repair and maintenance of energy equipment, and rent and other services; and operates retail stations. It sells its products in Russia, Europe, the Asia-Pacific region, the Middle East, North America, and internationally. PAO NOVATEK has a strategic cooperation agreement with Japan Bank for International Cooperation to cooperate on projects to produce hydrogen and ammonia, carbon capture, utilization, and storage technologies, as well as renewable energy projects in Russia. The company was formerly known as OAO NOVATEK and changed its name to PAO NOVATEK in October 2016. PAO NOVATEK was founded in 1994 and is based in Tarko-Sale, Russia.

Full NSTKF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NSTKF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NSTKF vs SCHDNSTKF vs JEPINSTKF vs ONSTKF vs KONSTKF vs MAINNSTKF vs ABBVNSTKF vs MRKNSTKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.